Approved regulatory verdict
Evidence outlook
Approved: Bladder Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Bladder Cancer · approved · Featured evidence · 1 approved Featured evidence · 1
Competitive landscape 2 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 2 same-indication.
Unlock with Research ↗ Drug Stage Modality Mechanism Evidence signal Reported efficacygraded featured trials N-803: this drug Approved Small molecule IL-15 superagonist NKTR-255 Phase 2 Biologic (subtype unspecified) IL-15 receptor IDE397 Phase 1/2 Small molecule MAT2A
Research Unlock the full comparison Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Unlock with Research ↗ Upcoming events (22 total) Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (3) November 2026 (1) Phase 2 Bladder Cancer Not yet recruiting
Est. primary completion 2026-11 ·
NCT06829823 ·
CT.gov ↗ What to watch December 2026 (2) Phase 2 Stage II Squamous Cell Carcinoma of the Head and Neck, Stage III Squamous Cell Carcinoma of the Head and Neck … Recruiting
Est. primary completion 2026-12-01 ·
NCT06161545 ·
CT.gov ↗ What to watch Phase 1/2 Endometrial Cancer, Cancer of Endometrium, Carcinoma of Endometrium, Endometrial Carcinoma Recruiting
Est. primary completion 2026-12-31 ·
NCT06253494 ·
CT.gov ↗ What to watch 2027 (9) March 2027 (1) Phase 2 Long COVID, Long COVID Syndrome, Long Covid 19 Recruiting
Est. primary completion 2027-03 ·
NCT07123727 ·
CT.gov ↗ What to watch May 2027 (1) Phase 2 Platinum-resistant Ovarian Cancer Recruiting
Est. primary completion 2027-05 ·
NCT06710288 ·
CT.gov ↗ What to watch June 2027 (2) Phase 2 Adenocarcinoma, Prostate Cancer, Neoplasms, Carcinoma, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type Not yet recruiting
Est. primary completion 2027-06-15 ·
NCT07574541 ·
CT.gov ↗ What to watch Phase 2/3 Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 … Active not recruiting
Est. primary completion 2027-06-30 ·
NCT05096663 ·
CT.gov ↗ What to watch July 2027 (1) Phase 2 Colorectal Carcinoma, Colorectal Neoplasm, Lynch Syndrome Active not recruiting
Est. primary completion 2027-07-01 ·
NCT05419011 ·
CT.gov ↗ What to watch August 2027 (1) Phase 2 Sepsis, Septic Shock, Lymphopenia, Immunosuppression, Critical Illness Not yet recruiting
Est. primary completion 2027-08-03 ·
NCT07578558 ·
CT.gov ↗ What to watch October 2027 (1) Phase 1/2 Metastatic Colorectal Cancer Recruiting
Est. primary completion 2027-10-31 ·
NCT06149481 ·
CT.gov ↗ What to watch December 2027 (2) Phase 2 HIV Enrolling by invitation
Est. primary completion 2027-12 ·
NCT07145164 ·
CT.gov ↗ What to watch Phase 2 Relapsed B-Cell Non-Hodgkin Lymphoma Not yet recruiting
Est. primary completion 2027-12 ·
NCT07477366 ·
CT.gov ↗ What to watch 2028 (3) January 2028 (1) Phase 1 Bladder Cancer Not yet recruiting
Est. primary completion 2028-01 ·
NCT07217496 ·
CT.gov ↗ What to watch February 2028 (1) Phase 2 Neuroblastoma Recurrent Recruiting
Est. primary completion 2028-02-01 ·
NCT07085338 ·
CT.gov ↗ What to watch September 2028 (1) Phase 3 NSCLC Stage IV Recruiting
Est. primary completion 2028-09 ·
NCT06745908 ·
CT.gov ↗ What to watch 2029 (4) January 2029 (1) Phase 2 Recurrent Prostate Cancer, Prostate Cancer Recruiting
Est. primary completion 2029-01-30 ·
NCT07686380 ·
CT.gov ↗ What to watch April 2029 (1) Phase 1 Prostate Cancer, Metastatic Prostate Cancer Not yet recruiting
Est. primary completion 2029-04-14 ·
NCT07756593 ·
CT.gov ↗ What to watch August 2029 (1) Phase 2 Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma … Active not recruiting
Est. primary completion 2029-08-31 ·
NCT03228667 ·
CT.gov ↗ What to watch December 2029 (1) Phase 2 Glioblastoma Active not recruiting
Est. primary completion 2029-12-31 ·
NCT06061809 ·
CT.gov ↗ What to watch 2030 (2) September 2030 (1) Phase 1 Myxoid Liposarcoma, Round Cell Liposarcoma, Synovial Sarcoma Recruiting
Est. primary completion 2030-09-02 ·
NCT07261657 ·
CT.gov ↗ What to watch December 2030 (1) Phase 2 HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer Not yet recruiting
Est. primary completion 2030-12-31 ·
NCT07628062 ·
CT.gov ↗ What to watch 2032 (1) July 2032 (1) Phase 1/2 Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent Recruiting
Est. primary completion 2032-07-31 ·
NCT07355205 ·
CT.gov ↗ What to watch See the full readout calendar ↗
All registered studies Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.
All indications (63) Bladder Cancer (5) Other / comorbidity (58)
Phase 3 (5) Phase 2/3 (2) Phase 2 (27) Phase 1/2 (13) Phase 1 (16) Appears in other studies (4)